The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections
Open accessAbstract
OBJECTIVES: Chronic infections of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients are intractable antibiotic targets because of their biofilm mode of growth. We have investigated the biofilm penetration, mechanism of drug release and in vivo antimicrobial activity of a unique nanoscale liposomal formulation of amikacin designed specifically for nebulization and inhaled delivery. METHODS: Penetration of fluorescently labelled liposomes into sputum or P. aeruginosa (PA3064) biofilms was monitored by a filter assay and by epifluorescence or confocal scanning laser microscopy. Amikacin release in vitro and rat lung levels after inhalation of nebulized material were measured by fluorescence polarization immunoassay. A 14 day agar bead model of chronic Pseudomonas lung infection in rats was used to assess the efficacy of liposomal amikacin versus free aminoglycosides in the reduction of bacterial count. RESULTS: Fluorescent liposomes penetrated readily into biofilms and infected mucus, whereas larger (1 microm) fluorescent beads did not. Amikacin release from liposomes was mediated by sputum or Pseudomonas biofilm supernatants. Rhamnolipids were implicated as the major releasing factors in these supernatants, active at one rhamnolipid per several hundred lipids within the liposomes. Inhaled liposomal amikacin was released in a slow, sustained manner in normal rat lungs and was orders of magnitude more efficacious than inhaled free amikacin in infected lungs. CONCLUSIONS: Penetration of biofilm and targeted, sustained release from liposomes can explain the superior in vivo efficacy of inhaled liposomal amikacin versus free drug observed in a 14 day infection model. Inhaled liposomal amikacin may represent an important therapy for chronic lung infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167
O'Toole, G. A., & Kolter, R. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00797.x · Cited by 2,537
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms
Singh, P. K., Schaefer, A. L., Parsek, M. R., Moninger, T. O., Welsh, M. J., & Greenberg, E. P. (2000) · Nature · doi:10.1038/35037627 · Cited by 1,519
Aminoglycoside antibiotics induce bacterial biofilm formation
Hoffman, L. R., D'Argenio, D. A., MacCoss, M. J., Zhang, Z., Jones, R. A., & Miller, S. I. (2005) · Nature · doi:10.1038/nature03912 · Cited by 1,321
Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U. E., Cekici, A., Meyer, K. C., Birrer, P., Bellon, G., Berger, J., Weiß, T., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci13870 · Cited by 1,099
Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation
Drenkard, E., & Ausubel, F. M. (2002) · Nature · doi:10.1038/416740a · Cited by 997
Walters, M. C., Roe, F., Bugnicourt, A., Franklin, M. J., & Stewart, P. S. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.317-323.2003 · Cited by 988
Spoering, A. L., & Lewis, K. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.23.6746-6751.2001 · Cited by 902
Rhamnolipid Surfactant Production Affects Biofilm Architecture in Pseudomonas aeruginosa PAO1
Davey, M. E., Caiazza, N. C., & O'Toole, G. A. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.3.1027-1036.2003 · Cited by 804
Parsek, M. R., & Greenberg, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.16.8789 · Cited by 652
The Lungs as a Portal of Entry for Systemic Drug Delivery
Patton, J. S., Fishburn, C. S., & Weers, J. G. (2004) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200409-049ta · Cited by 563
A Dose-Response Study of Antibiotic Resistance in Pseudomonas aeruginosa Biofilms
Brooun, A., Liu, S., & Lewis, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.640-646.2000 · Cited by 473
Role of CFTR in Airway Disease
PILEWSKI, J. M., & FRIZZELL, R. A. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.s215 · Cited by 447
A rat model of chronic respiratory infection with Pseudomonas aeruginosa.
Cash, H. A., Woods, D. E., McCullough, B., JOHANSON, W. G., & Bass, J. A. (1979) · PubMed · doi:10.1164/arrd.1979.119.3.453 · Cited by 327
Chmiel, J. F., & Davis, P. B. (2003) · Respiratory Research · doi:10.1186/1465-9921-4-8 · Cited by 254
Cystic Fibrosis Sputum: A Barrier to the Transport of Nanospheres
SANDERS, N. N., DE SMEDT, S. C., VAN ROMPAEY, E., SIMOENS, P., DE BAETS, F., & DEMEESTER, J. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.5.9909009 · Cited by 248
Ochsner, U. A., Snyder, A., Vasil, A. I., & Vasil, M. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082238299 · Cited by 210
Timing and Localization of Rhamnolipid Synthesis Gene Expression in Pseudomonas aeruginosa Biofilms
Lequette, Y., & Greenberg, E. P. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.1.37-44.2005 · Cited by 176
Chambless, J. D., Hunt, S. M., & Stewart, P. S. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.72.3.2005-2013.2006 · Cited by 172
Mugabe, C., Halwani, M., Azghani, A. O., Lafrenie, R. M., & Omri, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01547-05 · Cited by 169
Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U. E., Cekici, A., Meyer, K. C., Birrer, P., Bellon, G., Berger, J., Weiß, T., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200213870 · Cited by 166
Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating
Read, R. C., Roberts, P., Munro, N. C., et al. (1992) · Journal of Applied Physiology · doi:10.1152/jappl.1992.72.6.2271 · Cited by 134
Sabra, W. A., Kim, E.-J., & Zeng, A. (2002) · Microbiology · doi:10.1099/00221287-148-10-3195 · Cited by 130
Beaulac, C., Clement-Major, S., Hawari, J. A.-A., & Lagacé, J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.665 · Cited by 128
Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice
Knight, V., Koshkina, N. V., Waldrep, J. C., Giovanella, B. C., & Gilbert, B. E. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050965 · Cited by 102
Cantin, A. M., & Woods, D. E. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.4.9807166 · Cited by 87
Toxicologic Testing of Inhaled Pharmaceutical Aerosols
Wolff, R. K., & Dorato, M. A. (1993) · Critical Reviews in Toxicology · doi:10.3109/10408449309104076 · Cited by 77
Liposome-Encapsulated Antibiotics
Salem, I. I., Flasher, D., & Düzgüneş, N. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)91015-x · Cited by 68
Conley, J., Yang, H., Wilson, T., Blasetti, K. L., Dininno, V., Schnell, G., & Wong, J. P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1288 · Cited by 68
Marier, J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg317 · Cited by 61
THE APPLICATION OF CONFOCAL MICROSCOPY TO THE STUDY OF LIPOSOME ADSORPTION ONTO BACTERIAL BIOFILMS
Ahmed, K., Gribbon, P. M., & Jones, M. N. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120016195 · Cited by 43
On the Transport of Lipoplexes Through Cystic Fibrosis Sputum
Sanders, N. N., Rompaey, E. V., Smedt, S. C. D., & Demeester, J. (2002) · Pharmaceutical Research · doi:10.1023/a:1015139527747 · Cited by 34
Pseudomonas aeruginosa from Patients with Cystic Fibrosis Affects Function of Pulmonary Surfactant
Lema, G. M. C., Dryja, D., Vargas, I., et al. (2000) · Pediatric Research · doi:10.1203/00006450-200001000-00021 · Cited by 25
Cited by
Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections
Makabenta, J. M. V., Nabawy, A., Li, C.-H., Schmidt-Malan, S., Patel, R., & Rotello, V. M. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0420-1 · Cited by 1,397
Nano-Strategies to Fight Multidrug Resistant Bacteria—“A Battle of the Titans”
Baptista, P. V., McCusker, M. P., Carvalho, A., Ferreira, D. A., Mohan, N. M., Martins, M., & Fernandes, A. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01441 · Cited by 881
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
Lipid and polymer nanoparticles for drug delivery to bacterial biofilms
Forier, K., Raemdonck, K., De Smedt, S. C., Demeester, J., Coenye, T., & Braeckmans, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.055 · Cited by 464
Metadata
- Authors
- Meers, P., Neville, M., Malinin, V., Scotto, A. W., Sardaryan, G., Kurumunda, R., Mackinson, C., James, G., Fisher, S., & Perkins, W. R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-04
- Volume
- 61
- Issue
- 4
- Pages
- 859-868
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2144814819
- Cited by
- 345
- References
- 34
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.